Roche reports positive topline outcomes from DMD treatment trial

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys (delandistrogene moxeparvovec) as a gene therapy for treating Duchenne muscular dystrophy (DMD).